Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 15, 2020 (Event Date)
Reporting Period: Immediate event reporting regarding a material definitive agreement.
On June 15, 2020, IDEAYA Biosciences, Inc. entered into a Collaboration, Option and License Agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited ("GSK"). The agreement establishes a strategic partnership for IDEAYA's synthetic lethality programs targeting MAT2A, Pol Theta (POLQ), and Werner Helicase (WRN). The agreement is contingent upon receiving Hart Scott Rodino Antitrust Improvements Act (HSR) clearance.
Key Financial Metrics and Transaction Terms
This filing details a transaction structure rather than historical financial performance. Key financial terms include:
- Upfront Payment: GSK will pay IDEAYA $100,000,000 within ten business days of the agreement's effective date.
- Equity Commitment: GSK committed to purchase up to $20,000,000 of IDEAYA common stock in a private placement at the price per share of IDEAYA's next qualified underwritten public offering.
- Option Exercise Payment (MAT2A): GSK must pay $50,000,000 to exercise its exclusive option to license MAT2A products.
- Development Milestones:
- MAT2A: Up to $465 million per product.
- POLQ: Up to $485 million per product.
- WRN: Up to $485 million per product.
- Commercial Milestones: Up to $475 million per product for MAT2A, POLQ, and WRN.
- Royalties and Profit Share:
- MAT2A & WRN: 50% of U.S. net profits (with an opt-out right for royalties) and tiered royalties on global non-U.S. net sales (high single-digit to sub-teen double-digit percentages).
- POLQ: Tiered royalties on global net sales.
Material Changes and Program Specifics
The agreement alters the development and commercialization landscape for three specific programs:
- MAT2A Program: IDEAYA leads research and early clinical development. GSK holds an exclusive option to license the product after IDEAYA delivers Phase 1 monotherapy data. If the option is exercised, GSK leads later-stage global development. Cost sharing is 20% IDEAYA / 80% GSK, adjustable based on U.S. to global profit ratios.
- POLQ Program: GSK holds a global exclusive license. GSK leads clinical development and is responsible for all R&D costs. IDEAYA receives milestones and royalties.
- WRN Program: GSK holds a global exclusive license. GSK leads clinical development. Cost sharing is 20% IDEAYA / 80% GSK, adjustable based on profit ratios. IDEAYA receives milestones and profit share/royalties.
Guidance, Risks, and Contingencies
Contingencies: The agreement becomes effective only upon receipt of HSR Clearance. The MAT2A option exercise is also subject to HSR Clearance.
Risks and Termination:
- Either party may terminate for insolvency or uncured breaches.
- IDEAYA may terminate if GSK challenges IDEAYA patents.
- GSK may terminate the agreement in its entirety or on a target-by-target basis upon notice.
Exclusivity: Both parties are restricted from developing or commercializing other products targeting POLQ, WRN, or MAT2A for an agreed period, unless GSK does not exercise the MAT2A option or HSR clearance fails.
Management Commentary: The filing references a press release and a new corporate presentation (Exhibit 99.1 and 99.2) but does not contain specific forward-looking financial guidance beyond the contractual milestone potentials.
Investor Verification Checklist
- Verify the receipt of HSR Clearance to confirm the agreement's effective date and the timing of the $100 million upfront payment.
- Monitor IDEAYA's next qualified underwritten public offering to determine the price and timing of the $20 million GSK equity purchase.
- Track the progress of the MAT2A Phase 1 monotherapy clinical trial, as data delivery triggers GSK's option to exercise the license.
- Review the full text of the Collaboration, Option and License Agreement (to be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2020) for confidential terms omitted from this summary.
- Assess the impact of the cost-sharing adjustments based on future U.S. versus global profit ratios for MAT2A and WRN products.